Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
NCT ID: NCT01465282
Last Updated: 2013-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
160 participants
INTERVENTIONAL
2011-12-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CT 327 in the Treatment of Psoriasis Vulgaris
NCT00995969
Safety and Efficacy of CD10367 in Psoriasis Vulgaris
NCT03025282
Efficacy and Safety of TC Cream In Treating Patients With Psoriasis Vulgaris
NCT03372811
Tofacitinib Ointment For Chronic Plaque Psoriasis
NCT01831466
A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
NCT03895372
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.05% (w/w) CT327 ointment
0.05% (w/w) CT327 ointment applied BID for up to 8 weeks.
CT327 0.05%
0.05% CT327 (w/w) ointment
0.1% (w/w) CT327 ointment
0.1% (w/w) CT327 ointment applied BID for up to 8 weeks.
CT327 0.1%
0.1% CT327 (w/w) ointment
0.5% (w/w) CT327 ointment
0.5% (w/w) CT327 ointment applied BID for up to 8 weeks.
CT327 0.5%
0.5% CT327 (w/w) ointment
Placebo ointment
Placebo ointment
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT327 0.05%
0.05% CT327 (w/w) ointment
CT327 0.1%
0.1% CT327 (w/w) ointment
CT327 0.5%
0.5% CT327 (w/w) ointment
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable psoriasis vulgaris
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Creabilis SA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hotsprings, Arkansas, United States
San Ramon, California, United States
Bay City, Michigan, United States
Fridley, Minnesota, United States
South Euclid, Ohio, United States
Portland, Oregon, United States
San Antonio, Texas, United States
Spanish Fork, Utah, United States
Birmingham, , United Kingdom
Cardiff, , United Kingdom
Glasgow, , United Kingdom
Manchester, , United Kingdom
Merseyside, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CT327-2003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.